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a new In Vivo Model to study 
Protective immunity to Zika Virus 
infection in Mice With intact Type i 
interferon signaling
Loulieta Nazerai, Amalie Skak Schøller, Peter Overbeck Sharma Rasmussen, Søren Buus, 
Anette Stryhn, Jan Pravsgaard Christensen and Allan Randrup Thomsen*
Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
The association between recent Zika virus (ZIKV) infection and neurological complica-
tions, microcephaly in the fetus, and Guillain–Barré syndrome in adults underscores the 
necessity for a protective vaccine. Rational vaccine development requires an in-depth 
understanding of the mechanisms which could protect against infection with this virus. 
However, so far, such an analysis has been hampered by the absence of a suitable 
small animal model. Unlike the situation in humans, ZIKV only replicates effectively in the 
peripheral organs of mice, if type I IFN signaling is interrupted. As type I IFN also impacts 
the adaptive immune response, mice with such a defect are not optimal for a compre-
hensive immunological analysis. In this report, we show that even in wild-type (WT) mice 
i.c. infection with low doses of virus causes marked local virus replication and lethal 
encephalitis in naïve mice. Furthermore, peripheral infection of WT mice with low doses 
of virus induces a significant immune response, which provides long-lasting protection 
of WT mice from a fatal outcome of subsequent i.c. challenge. Therefore, combining 
peripheral priming with later i.c. challenge represents a new approach for studying 
the adaptive immune response to ZIKV in mice with an intact type I IFN response. In 
this study, we focused on the mechanisms underlying resistance to reinfection. Using 
a combination of adoptive transfer, antibody-based cell depletion, and gene targeting, 
we show that the key protective factor in type I IFN replete mice is humoral immunity. 
CD8 T  cells are not essential in mice with preformed specific antibodies, but under 
conditions where initial antibody levels are low, effector CD8 T cells may play a role as 
a back-up system. These results have important implications for our understanding of 
natural immunity to ZIKV infection and for Zika vaccine design.
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inTrODUcTiOn
Zika virus (ZIKV) is one of the most recent viral pathogens to cause global public health concern. 
Nevertheless, ZIKV is not a newly identified virus since it was first isolated almost 70 years ago from a 
sentinel monkey in the Zika forest in Uganda, and it has since been assigned to the flaviviridae family of 
positive-stranded RNA viruses along with yellow fever, Dengue, West Nile, and Japanese Encephalitis 
virus (1). The first human case was reported in 1954, and by the end of the twentieth century, the virus 
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was detected in a wide geographical area, including Thailand, 
Philippines, Vietnam, Indonesia, Malaysia, Pakistan, and India 
(2–4). In spite of its wide geographical distribution, the virus 
had maintained a relatively low profile until 2007 with only 14 
documented cases of human disease attributed to ZIKV infection. 
Therefore, the ZIKV outbreak on the Micronesian island of Yap 
that year, which resulted in 70% of the population being infected, 
raised considerable concern (5). A larger outbreak followed in 
2013 in French Polynesia, while in 2015, ZIKV emerged in 
the Americas for the first time and within a year had spread to 
over 50 countries (6, 7). Its fast paced global spread combined 
with accumulating evidence linking prenatal ZIKV infection to 
an increased rate of babies born with microcephaly and other 
neurodevelopmental abnormalities led the WHO to declare it a 
public health emergency of international concern (8, 9). In addi-
tion to neonatal microcephaly, ZIKV infection has been shown 
to affect also the adult population by attacking the peripheral 
nervous system and causing a neurodegenerative disease called 
Guillain–Barré syndrome in a few infected people (10, 11).
The ZIKV genome consists of a single-stranded, positive-sense 
RNA of approximately 11  kb in length and it encodes a single 
open reading frame. Translation of the viral RNA generates one 
polyprotein that is subsequently proteolytically processed into 
10 mature proteins: 3 structural (C, prM/M, and E) and 7 non-
structural (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) (12). 
Cryo-electron microscopy studies have revealed a high similarity 
in virion organization and structure of ZIKV with other flavivi-
ruses, especially Dengue virus types 3 and 4 (13–15). However, 
despite the similarity at the molecular level that ZIKV shares with 
other flaviviruses, it is distinct in its ability to cause transplacental 
infection, fetal abnormalities, and vector independent transmis-
sion through body fluids in humans (16, 17).
In humans, ZIKV suppresses host innate immune response 
by employing multiple strategies to block the induction of type-I 
IFN as well as downstream IFN-stimulated genes. The virus has 
been found to cause degradation of the antiviral transcriptional 
activator STAT-2 ultimately resulting in reduced type I/III IFN-
mediated signaling (18, 19). The efficient evasion of type I IFN 
responses allows the virus to replicate to substantial titers and 
cause disease in humans. In mice, however, probably due to some 
species-specific immune evasion mechanisms, peripheral viral 
replication is limited and does not suffice to cause significant 
pathology. To enable its study, several murine models have been 
developed most of them with an absent or suppressed type I IFN 
signaling to allow viral replication (20–22). These models haven 
proven useful in characterizing certain aspects of ZIKV infection; 
however, there are intrinsic limitations as to what you can learn 
about the adaptive antiviral defense in biological systems where 
a critical component of the early host response is absent. Bearing 
that in mind, an animal model with an intact innate immune 
system is likely to prove advantageous in elucidating the complex 
interplay of the host’s immune system with ZIKV.
In this study, we have used two different strains of adult wild-
type (WT) mice with an intact immune system to establish an 
in vivo model of ZIKV infection and characterize aspects of ZIKV 
protective immunity. For this purpose, we have utilized a number 
of gene-targeted mouse strains lacking critical components of the 
adaptive immune system and performed in  vivo cell depletion 
as well as adoptive transfer assays, and we clearly document the 
dominant role of antibodies (Abs) in clinical protection but also 
a potential contribution of cell-mediated immunity.
MaTerials anD MeThODs
Mice
Female BALB/c and C57BL/6 (B6) wild-type (WT) mice as well as 
β2-microglobulin-deficient (β2m−/−) and MHC class II-deficient 
(Aβ−/−) mice on a B6 background were obtained from Taconic 
farms and maintain under specific pathogen-free conditions. 
B cell-deficient mice (μMT/μMT, B6.129S2-Igh-6tm1Cgn/J), 
TCRβ-deficient mice (TCRβ−/−, B6.129P2-Tcrbtm1Mom/J), CD8- 
deficient mice (CD8−/−, B6.129S2-Cd8atmMak/J), CXCR5-
deficient (CXCR5−/−, B6.129S2(Cg)-Cxcr5tm1Lipp/J) mice, and 
CD40L-deficient (CD40L−/−, B6.129S2-Cd40lgtm1lmx/J) mice 
were all obtained from the Jackson Laboratory (Bar Harbor, ME, 
USA). IFN-γ/perforin double-deficient (IFN-γ/Prf−/−) mice on a 
B6 background were produced as previously described (23) and 
maintained locally.
All mice used in this study were 7–10  weeks old and were 
housed under SPF conditions at the ALAAC accredited animal 
facility at the Panum Institute (Copenhagen, DK). Mice coming 
from outside sources were allowed to rest for at least 1  week 
before entering an experiment.
Virus Preparation and Quantitation
Zika virus, strain MR766 (Uganda, 1947), was obtained from 
American Type Culture Collection (ATCC) (Manassas, VA, 
USA) and was propagated in Vero cells (ATCC CCL-81) grown in 
DMEM containing 10% FBS, glutamine, and antibiotics (penicil-
lin and streptomycin). The titer of the virus stock was determined 
based on the number of plaque-forming units (pfu) in semi-
confluent monolayers of Vero cells. Specifically, 10-fold serial 
dilutions of the virus stock were prepared and incubated for 2 h 
on Vero cell monolayers that were seeded a day earlier in 24-well 
plates. After the 2 h incubation, cells were overlayed with medium 
containing 0.9% methylcellulose and were further incubated for 
5 days (37°C, 5% CO2). After fixation with 4% formaldehyde, cells 
were stained with 0.1% crystal violet for plaque visualization.
For quantitation of virus in the organs of mice, the organs were 
first homogenized in PBS to yield 10% suspensions and viral titers 
were subsequently determined as described above. The detection 
limit of the assay was 250 pfu/g of organ.
For the experiments regarding yellow fever virus (YFV), virus 
stock of strain YF-17D was produced and quantified as previously 
described (24).
immunization and i.c. challenge
Unless stated otherwise, mice were immunized by i.v. injection 
of 1 × 103 pfu ZIKV MR766 in 300 µl. During viral challenge, 
the mice were deeply anesthetized and, unless otherwise stated, 
1 × 103 pfu ZIKV MR766 in 30 µl was inoculated i.c. Health status 
and weight were monitored daily after i.c. challenge, and mice 
were euthanized when severe signs of illness along with a weight 
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loss of or exceeding 25% of the initial weight were recorded. 
Immunization with YFV was done and mice were monitored as 
previously described (24).
Titration of neutralizing ab
Neutralizing antibodies in the serum of mice immunized with 
ZIKV were determined by an in  vitro plaque reduction assay. 
Twofold dilutions of the mouse sera were prepared using Vero 
cell media (DMEM 1965 NaHCO3 medium supplemented with 
penicillin and streptomycin, l-glutamine, Na-pyruvate, and 1% 
FBS) and incubated for 1 h (37°C, 5% CO2) with approximately 
50  pfu ZIKV. The mixtures were subsequently transferred in 
duplicates to 24-well plates that had been seeded the day before 
with 1 × 105 VERO cells per well. The plates were incubated for 
2 h (37°C, 5% CO2) before the addition of the overlay medium 
and further incubated for 5  days. The plaques formed in each 
well were visualized and counted as previously described, and 
the neutralizing antibody titers were determined based on the 
highest serum dilution that neutralized more than 50% of the 
viral plaques.
Flow cytometry analyses
Spleens were removed aseptically and transferred to Hanks Balanced 
Salt Solution (HBSS). Single-cell suspensions were obtained 
by pressing the spleens through a 70-µm nylon cell strainer, fol-
lowed by centrifugation and two washes in HBSS. Approximately 
2 × 106 splenocytes were transferred to U-bottom 96-well micro-
titer plates and were incubated for 20 min (4°C in the dark) with 
PE-conjugated H-2Db tetramers for ZIKV E294–302 (25) and sub-
sequently stained for an additional 20 min (4°C in the dark) for 
relevant cell-surface markers. Cells to be stained for intracellular 
granzyme B were then permeabilized using the BD Biosciences 
FoxP3 staining protocol. Next, the cells were centrifuged, washed, 
fixed in 1% PFA, and finally resuspended in PBS and stored at 
4°C until flow cytometric analysis. Cell samples were analyzed 
using FACS LSRFortessa cytometer (BD Biosciences), and the 
data were analyzed using FlowJo software version 10 (Tree Star).
In Vivo cD4 and/or cD8 T-cell Depletion
A combination of two monoclonal antibodies (YTS 169 and YTS 
156) was used for in vivo depletion of CD8 T cells, while YTS191 
was used for in vivo depletion of CD4 T cells; hybridomas pro-
ducing these monoclonals were kindly provided by S. Cobbold 
(Sir Williams Dunn School of Pathology, Oxford, U.K.) (26). Mice 
to be depleted were injected i.p. with 200 µg of relevant antibody 
or antibody combination 1 day prior to i.c. challenge and with 
100 µg of antibody 1 and 4 days post challenge. The efficiency of 
the cell depletion was confirmed by flow cytometric analysis of 
splenocytes on day 7 post i.c. challenge.
adoptive Transfer of serum or 
splenocytes
Serum was collected from mice immunized with 1 × 103 pfu/300μl 
i.v. ZIKV 4 weeks earlier, and was transferred to naive recipient 
mice. Mice received 500 µl serum i.v. and 500 µl serum i.p. 3 days 
prior to i.c. challenge and 300 µl serum i.v. again 1 day before i.c. 
challenge. We have previously found that this regimen results in 
serum Ab levels about 1/3 of that in the donor serum (27, 28). 
Serum from naive mice was used as control.
Splenocytes were collected from similarly immunized mice 
and transferred to HBSS. Single-cell suspensions were obtained 
by pressing the spleens through a fine mesh (70 µm) followed by 
centrifugation and two washes in HBSS, after which cells were 
counted, and 7 × 107 cells were injected i.v. into naive recipient 
mice 2 days prior to i.c. challenge. Splenocytes from naive mice 
or PBS were used as control.
statistical evaluation
GraphPad Prism Software (version 7) was used for the statistical 
analysis. Quantitative results were compared using a nonparamet-
ric Mann–Whitney U-test and a p-value of <0.05 was considered 
evidence of a statistically significant difference.
resUlTs
WT immunocompetent Mice are 
susceptible to i.c. infection With ZiKV
Peripheral inoculation of ZIKV does not cause readily detect-
able disease in WT mice. Given that a WT mouse model would 
be of great importance in studying ZIKV pathogenesis, and 
based on our experience from working with a mouse model for 
YFV (24), we wanted to investigate whether we could induce 
clinical disease by introducing ZIKV directly into the brain of 
WT mice.
To that end, we challenged two different strains of WT mice 
(C57BL/6 and BALB/c) intracerebrally (i.c.) with 1 × 102, 1 × 103, 
or 1 × 104 pfu of ZIKV and monitored their health and weight 
daily (data not shown). Unlike infection by the intravenous (i.v.) 
route, which did not lead to significant morbidity in any of the 
tested strains, i.c. infection induced almost the same pattern of 
severe disease in both mouse strains. In C57BL/6 mice, all three 
i.c. doses resulted in acute weight loss starting around day 4 post 
infection that progressed into severe disease by day 8 post infec-
tion, at which time point mice had lost more than 25% of their 
initial weight and had to be euthanized (Figure 1A). In BALB/c 
mice, the intermediate and high i.c. doses gave the same survival 
pattern as in C57BL/6, while some of the mice challenged with 
the lowest dose survived (Figure 1B). This suggests that, while 
minor differences may exist between the two mouse strains, the 
overall pattern was more or less the same.
In order to have a lethal challenge dose that would yield uni-
form pathogenesis in both strains, yet at the same time would not 
overwhelm the mice with high viral loads that might potentially 
impend the observation of small immunological differences, we 
chose to use the intermediate i.c. dose (1 × 103 pfu) for the rest of 
our challenge experiments.
Peripheral inoculation With low Doses  
of ZiKV Protects WT Mice against 
subsequent lethal i.c. infection With ZiKV
Consistent with findings from recent studies (22, 29), we did not 
observe any clinical signs of disease when we introduced the virus 
FigUre 1 | Determination of a suitable dose for i.c. challenge. Wild-type C57BL/6 (a) and BALB/c (B) mice were infected with 1 × 102, 1 × 103, or 1 × 104 pfu Zika 
virus (ZIKV) i.c., and their weight, health, and survival were monitored daily for 16 days. Groups of mice injected with 1 × 103 pfu ZIKV i.v. or PBS i.c. were included 
for comparison. A weight loss of 25% or more of initial body weight was used as humane end-point. n = 5 mice/group, *p < 0.05.
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peripherally (Figure 1) and we were not able to detect production 
of infectious virus (<250 pfu/g organ) neither in blood nor in a 
number of organs tested (spleen, liver, and kidney).
To investigate if such an asymptomatic “infection” might 
impact the outcome of an otherwise lethal i.c. infection with ZIKV, 
we infected WT C57BL/6 and BALB/c mice i.v. with three differ-
ent doses of ZIKV (1 × 103, 1 × 104, or 1 × 105 pfu) and 4 weeks 
later all mice received a lethal dose of ZIKV i.c. On day 7 post 
i.c., brains were removed and organ virus titers were determined 
by a plaque assay. We observed that all mice that had previously 
received the virus peripherally were able to preserve their body 
weight and prevent lethal disease by successfully controlling viral 
replication in their brains. By contrast, matched naive mice were 
unable to control the infection and experienced a severe weight 
loss associated with high viral loads in their brains on day 7 post 
i.c. challenge (Figures 2A,D).
The fact that even a relatively low (1 × 103) dose of ZIKV given 
i.v. was able to induce full protection against an otherwise lethal 
i.c. challenge was interesting, and we wanted to further gage 
the efficiency of this protection. Thus, WT C57BL/6 mice were 
infected with 1 ×  103 ZIKV i.v., and 4  weeks later, these mice, 
along with a group of naive control mice, received a lethal i.c. 
challenge of ZIKV. Health and weight were monitored daily and 
brains were removed on days 3, 5, and 7 post i.c. challenge, and the 
levels of infectious virus in the CNS at these times were measured 
by a plaque assay (Figure 3). Unlike the situation in other organs, 
ZIKV replicated to high titers in the CNS of i.c. infected, naïve 
WT mice. Thus significant levels of virus were detected in the 
CNS already by day 3 post i.c. challenge, and even higher levels 
were measured by days 5 and 7 post i.c. challenge, coinciding 
with increased severity of the clinical disease. By contrast, mice 
peripherally inoculated with virus 4 weeks prior to i.c. challenge 
were not only able to clear the infection before onset of clinical 
symptoms, but already by day 3 after i.c. challenge, we could not 
find infectious virus in their brains.
Hence, we had established a model where strong protection 
against lethal i.c. infection is induced in WT mice through an 
asymptomatic primary i.v. infection with low doses of ZIKV 
(Figure 4). Remarkably, similar clinical protection was observed 
when the peripheral inoculation was performed via the subcuta-
neous route (Figure S1 in Supplementary Material).
Primary asymptomatic ZiKV infection 
induces Both abs and cD8 T cell 
responses in WT Mice
The fact that peripheral administration of a low ZIKV inoculum 
leads to asymptomatic infection closely resembles the course of 
ZIKV infection in humans, which is mostly subclinical with only 
20% of the infected people developing flu-like symptoms (30). 
Additionally, studies of human immune responses to ZIKV infec-
tion have revealed the induction of both B and T cell responses 
in the acute phase of infection (31). Therefore, we sought to 
investigate whether low doses of ZIKV could invoke humoral 
and/or cellular immune responses despite the lack of detectable 
infection in the peripherally inoculated WT mice.
To that end, WT C57BL/6 mice were infected with 1 × 103 pfu 
ZIKV i.v., and we assessed the levels of neutralizing Abs in the 
serum of infected WT mice on days 7, 14, 21, and 28 post i.v. 
infection by an in vitro plaque reduction assay. Briefly, serial dilu-
tions of the serum were incubated with ZIKV and the reduction 
in plaque formation on Vero cells monolayers was measured 
and translated into neutralizing potency. We observed that the 
neutralizing potential of the Abs in the serum was already highly 
significant on day 7 post i.v.; it increased further on day 14 and 
remained at the same high level until at least day 28, the last day 
tested (Figure 5A).
Additionally, we assessed the ZIKV-induced T cell response 
in the spleen on days 3, 6, 8, 10, 15, and 30 post i.v. A CD8 
T-cell response was detected by flow cytometric analysis using 
surface staining reflecting T-cell activation (VLA-4 and CD44) 
and/or tetramer staining for ZIKV-specific CD8 T  cells alone 
or in combination with intracellular staining for granzyme B 
production (Figure 5B; for representative plots, see Figure S2 in 
FigUre 2 | Determination of a suitable dose for i.v. immunization. Wild-type C57BL/6 (a,B) and BALB/c (c,D) mice were inoculated with 1 × 103, 1 × 104, or 
1 × 105 pfu Zika virus (ZIKV) i.v., and 4 weeks later, these mice and naïve controls were challenged with 1 × 103 pfu ZIKV i.c. Mice were weighed daily (a,c), and on 
day 7 post i.c. challenge, brains were removed and viral titers were measured by a plaque assay (B,D). The detection limit for virus in the brain was 250 pfu/g organ. 
Each dot represents an individual animal and bars the medians of the groups. The weight curves (a,c) depict the group medians. n = 3–4 mice/group, *p < 0.05. 
For the weight curves, the color of the star denotes the infected group, which forms the basis for statistical comparison with naïve mice.
FigUre 3 | Kinetics of virus control after i.c. challenge. Wild-type C57BL/6 mice were inoculated with 1 × 103 pfu Zika virus (ZIKV) i.v., and 4 weeks later, these 
mice and naïve controls were challenged with 1 × 103 pfu ZIKV i.c. Mice were weighed and monitored daily (a), and on days 3, 5, and 7 post i.c. challenge, brains 
were removed and viral titers were measured by a plaque assay (B). The detection limit for virus in the brain was 250 pfu/g organ. Each dot represents an individual 
animal and bars the medians of the groups. The weight curves depict the group medians. n = 3–5 mice/group, *p < 0.05.
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FigUre 5 | Cellular and humoral responses to Zika virus (ZIKV) infection in wild-type (WT) mice. WT C57BL/6 mice were inoculated with 1 × 103 pfu ZIKV i.v. On 
days 7, 14, 21, and 28 post i.v. inoculation, sera were collected and ZIKV-specific Abs were determined by an in vitro plaque reduction assay. Each dot represents 
one mouse; bars denote group medians (a). On days 3, 6, 8, 10, 15, and 30 post i.v. inoculation, spleens were harvested and total numbers of activated 
(CD44highVLA-4high) CD8 T cells, total numbers of antigen-specific [tetramer+ (H-2Db/E294–302)] CD8 T cells as well as the percentage of antigen-specific CD8 T cells 
producing granzyme B were determined by flow cytometry (B). On same days as in panel (B), splenocytes were stained with anti-CD4 and Th1 polarized (Ly-6Chigh) 
cycling (Ki-67+) CD4 T cells were enumerated. Panels (B, c) depict medians and ranges; n = 5–10 mice/time point (c).
FigUre 4 | Graphical representation of our in vivo mouse model for Zika virus (ZIKV) infection. Mice are infected peripherally with low doses of ZIKV, and 4 weeks 
later, they are challenged i.c. with lethal doses of ZIKV.
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FigUre 6 | How quickly is protection induced? Wild-type C57BL/6 mice were inoculated with 1 × 103 pfu Zika virus (ZIKV) i.v. and on days 4 (a,B) or 7 (c,D) post 
i.v. inoculation mice were challenged with 1 × 103 pfu ZIKV i.c. Mice were weighed and monitored daily (a,c), and on day 7 post i.c. challenge, brains were removed 
and viral titers were measured by a plaque assay (B,D). Groups of naïve mice were used as negative controls. The detection limit for virus in the brain was 250 pfu/g 
organ. Each dot represents an individual animal, and bars represent the medians of the groups. The weight curves depict the group medians. n = 4–5 mice/group, 
*p < 0.05. The complete resistance observed 7 days post immunization was confirmed in a second experiment.
7
Nazerai et al. Immunity to Reinfection With ZIKV
Frontiers in Immunology | www.frontiersin.org March 2018 | Volume 9 | Article 593
Supplementary Material). We found that, shortly after ZIKV infec-
tion, numbers of activated CD8 T cells increased markedly and 
antigen-specific CD8 T cells directed toward a single viral epitope 
could account for about 50% of these cells. The response peaked 
between 6 and 8 days post i.v. and had decreased substantially 
by day 10 post i.v. As further evidence pointing to the effector 
function of these cells, we observed the presence of granzyme B 
in many of the cells, suggesting that they represented a population 
of activated CD8 T cells with the capacity to kill virus-infected 
cells (32). We also detected a significant CD4 T cell response; in 
this case we had no epitope-specific population to look for, so to 
increase the resolution regarding recently generated Th1 effector 
cells, we used a combination of the Th1 activation marker Ly-6C 
(33, 34) and expression of Ki-67. Again, we found a significant 
response peaking around 6–10 days after infection. Thus, despite 
very limited viral infection, a potent immune response was 
induced in low dose, i.v. infected mice.
Fast and long-lasting clinical Protection 
in WT Mice experiencing a Primary 
asymptomatic ZiKV infection
Next, we wondered how early are mice protected by a primary 
asymptomatic ZIKV infection and how long does the protection last?
To investigate when protective immunity is obtained, WT 
C57BL/6 mice were immunized with 1 × 103 pfu ZIKV i.v. and 
either 4 or 7 days later, they received a lethal challenge dose of 
ZIKV i.c. (Figure  6). We observed that the viral burden was 
significantly reduced in mice immunized 4  days prior to i.c. 
challenge while ZIKV was undetectable in the CNS of mice 
immunized 7 days prior to the challenge. As always, naive mice 
were incapable of controlling viral replication in the brain. This 
indicated the capacity of an asymptomatic ZIKV infection to 
induce a fully protective immune response within 1 week follow-
ing immunization, roughly coinciding with the appearance of 
neutralizing Abs and a potent virus-specific CD8 T cell response 
(cf. Figure 5).
To test how long after a single peripheral infection mice 
would still be protected against lethal infection, WT C57BL/6 
mice were immunized as previously described and left for either 
3 or 8  months prior to i.c. challenge (Figure  7). We saw that 
peripherally infected mice stayed clinically protected for at least 
8 months and successfully controlled the lethal challenge at this 
point. In the same way, long-term protection (3 and 8 months 
post ZIKV immunization) was assessed also in WT BALB/c mice 
with similar results (Figure S3 in Supplementary Material).
To further gage the induced protection in our model, we 
tested how mice that were peripherally inoculated 4 weeks earlier 
would respond to i.c. challenge with much higher doses (1 × 105 
or 1 ×  106  pfu) of ZIKV. We observed that, for both C57BL/6 
and BALB/c mice and for both challenge doses, no infectious 
virus could be isolated from the CNS 3  days after challenge, 
FigUre 7 | Longevity of protection. Wild-type C57BL/6 mice were inoculated with 1 × 103 pfu Zika virus (ZIKV) i.v. and 3 (a,B) or 8 (c,D) months post i.v. 
inoculation mice were challenged with 1 × 103 pfu ZIKV i.c. Mice were weighed and monitored daily (a,c), and on day 7 post i.c. challenge, brains were removed 
and viral titers were measured by a plaque assay (B,D). Mice were weighed and monitored daily, and on day 7 post i.c. challenge, brains were removed and viral 
titers were measured by a plaque assay. Groups of naïve mice were used as negative controls. The detection limit for virus in brain was 250 pfu/g organ. Each dot 
represents an individual animal, and bars represent the medians of the groups. The weight curves depict the group medians. n = 4–5 mice/group, *p < 0.05. Similar 
results were obtained in BALB/c mice (see Figure S2 in Supplementary Material).
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while substantial amounts of infectious virus was isolated from 
the CNS of matched naive controls (Figure S4 in Supplementary 
Material).
Taken together, these results indicate that the immunity induced 
by an asymptomatic primary ZIKV infection comes fast is long 
lasting and is not breached even when high doses of ZIKV are 
administered i.c. Moreover, the induced protection is virus 
specific since i.c. challenge of ZIKV-immunized WT mice with 
lethal doses of YFV, a closely related flavivirus, was not efficiently 
controlled (Figure  8). In agreement with studies suggesting 
immunological cross-reactivity between different flaviviruses, we 
noticed that exposure to primary ZIKV infection prior to YFV 
i.c. challenge leads to a significantly reduced YFV load in the 
CNS—albeit not to the level required for full protection.
Transfer of immune serum, but not 
immune splenocytes, Protect naive  
Mice From lethal ZiKV i.c. infection
Having established the ability of an asymptomatic primary ZIKV 
infection to induce effective and stable protection against i.c. 
challenge, we next wanted to shed light on which arm of the 
immune response was crucial in mediating this protection.
To evaluate the role of Abs in protection, WT C57BL/6 mice 
were immunized with 1 × 103 pfu ZIKV i.v., and 4 weeks later, 
whole serum was harvested and transfused into naive recipient 
mice as described in Section “Materials and Methods.” Serum 
collected from naive mice was transferred to a control group. All 
recipient mice were challenged i.c. with a lethal dose of ZIKV 
3  days after the first serum transfer (for details, see Materials 
and Methods), and their brains were removed on day 7 post i.c. 
(Figure 9A). While the mice receiving immune serum were fully 
protected against the i.c. challenge, the control mice receiving the 
naïve serum were not protected and developed high viral titers in 
the CNS on day 7 after challenge.
To address whether cellular components played a role in pro-
tection, we performed adoptive transfer of 7 × 107 ZIKV-primed 
splenocytes (coming from the same immunized mice as above) 
into naive recipients 2  days prior to i.c. challenge; splenocytes 
collected from naive mice (or PBS) were transferred to a group 
of naive recipient mice as a control (Figure 9B). By contrast to 
primed-serum, transferred primed splenocytes only slightly 
reduced the viral load in the CNS and only when the effect was 
measured on day 8 post i.c. challenge. When the viral loads 
were measured on day 7 post i.c., no reduction in viral load was 
observed.
Overall, these results suggest that humoral immunity is suf-
ficient for protection; however, a potential contribution of cellular 
immunity, particularly when specific Abs are lacking, cannot be 
excluded.
FigUre 8 | The induced protection is virus-specific. Wild-type C57BL/6 mice were inoculated with 1 × 103 pfu Zika virus (ZIKV) i.v. and 4 weeks later were 
challenged i.c. with either 1 × 103 pfu ZIKV or 1 × 104 pfu YF-17D. Mice were weighed and monitored daily (a), and on day 7 post i.c. challenge, brains were 
removed and viral titers were measured by a plaque assay (B). Groups of naïve mice were used as negative controls. The detection limit for virus in the brain 
was 250 pfu/g organ for both viruses. Each dot represents an individual animal, and bars represent the medians of the groups. The weight curves depict the 
group medians. n = 4–5 mice/group, *p < 0.05, mice challenged with the same virus are compared. The results of one of two identical experiments are 
depicted.
FigUre 9 | Immune serum transfer confers full protection against Zika virus (ZIKV), while primed splenocytes are marginally effective. Wild-type C57BL/6 mice were 
inoculated with 1 × 103 pfu ZIKV i.v., and 4 weeks later, serum and splenocytes were harvested for adoptive transfer to naïve recipients. (a) Naïve mice received the 
immune serum 3 and 1 days prior to i.c. challenge with 1 × 103 pfu ZIKV. On day 7 post i.c. challenge, brains were removed and viral titers were measured by a 
plaque assay. (B) Naïve mice received primed splenocytes 2 days prior to i.c. challenge with 1 × 103 pfu ZIKV. Mice were weighed and monitored daily and on days 
7 and 8 post i.c. challenge, brains were removed and viral titers were measured by a plaque assay. Groups of naïve mice, receiving serum or splenocytes (PBS) from 
naïve donors were included as negative controls. The detection limit for virus in the brain was 250 pfu/g organ. Each dot represents an individual animal, and bars 
represent the medians of the groups. n = 3–5 mice/group,*p < 0.05.
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FigUre 10 | Both B and T cells are essential for induced protection against Zika virus (ZIKV). TCRβ-deficient (TCRβ−/−) (a) and B cell-deficient (μMT) (B) mice were 
inoculated with 1 × 103 pfu ZIKV i.v. and 4 weeks later were challenged with 1 × 103 pfu ZIKV i.c. A group of μMT-deficient mice were depleted of CD8 T cells 
(αCD8) prior to i.c. challenge. On day 7 post i.c. challenge, brains were removed and viral titers were measured by a plaque assay. For all deficient mice, a group of 
uninfected deficient mice was included for control. Additionally, wild-type (WT) C57BL/6 mice, inoculated with 1 × 103 pfu ZIKV i.v., and naive uninfected mice were 
used as positive and negative controls, respectively. The detection limit for virus in the brain was 250 pfu/g organ. Each dot represents an individual animal, and bars 
represent the medians of the groups. n = 4–10 mice/group, *p < 0.05.
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Both B and T cells are Pivotal for the 
Protection against a lethal Outcome of 
i.c. infection With ZiKV
To further explore the role of adaptive immunity in protecting mice 
against a lethal outcome of i.c. challenge with ZIKV, B cell-deficient 
(μMT) and TCR αβ-deficient (TCRβ−/−) mice were compared to 
WT mice for their ability to resist a lethal ZIKV i.c. challenge when 
previously immunized with 1 × 103 pfu ZIKV i.v. Naive mice of 
each mouse strain were included for control (Figure 10). We noted 
that, during the priming phase none of the immunodeficient mice 
displayed any obvious clinical signs of disease, which supports the 
notion that ZIKV control following peripheral inoculation can 
be mediated via innate immune mechanisms (35). Nevertheless, 
neither B nor T cell-deficient mice benefited from prior immuni-
zation and, unlike WT mice, were unable to clear ZIKV from the 
CNS when challenged i.c. This highlights the importance of B and 
T cells to mount protective immune responses that can save the 
mice from subsequent lethal challenge.
Notably, when B  cell-deficient mice were depleted of CD8 
T cells immediately prior to i.c. challenge, the viral burden was 
found to be slightly, but significantly higher than the viral load 
in the brains of undepleted mice (Figure 10). By comparison, in 
WT mice where Ab production is intact, depletion of CD8 and/
or CD4 T cells did not alter the outcome of i.c. challenge, and 
all depleted immunized mice seemed equally efficient at clearing 
ZIKV from the CNS (Figure  11). Therefore, given that B  cell-
deficient mice are unable to produce Abs, these results support 
the notion that CD8 T cells may contribute to virus control in the 
absence of specific Abs.
It is also worth pointing out that primary adaptive immune 
components appear to play a role in the course of infection 
following i.c. challenge in naive mice, since both naïve B and 
T cell-deficient mice displayed significantly higher viral loads in 
the CNS than matching WT mice.
cD4 T cells are required for Protection 
against subsequent i.c. infection, While 
cD8 T cells Might Function as a Back-up 
Mechanism
Even though in  vivo depletion of T  cells prior to i.c. challenge 
did not impair the level of protection in immunized WT mice, 
that finding does not exclude a significant contribution of T cells 
in the priming/immunization phase or as tissue resident effector 
cells. Therefore, we next sought to investigate the role of T cells 
using a range of genetically modified mice with targeted immune 
defects within the T cell compartment.
We started by studying the contribution of CD8 T  cells. 
We administered 1 ×  103 pfu ZIKV i.v. to CD8α-deficient, β2-
microblobulin-deficient, and perforin/IFN-γ double-deficient 
mice, and 4 weeks later we compared the outcome of i.c. challenge 
to that in WT mice. Naive mice of each mouse strain were included 
for control. We observed that immunized CD8-deficient and the 
majority of β2-microglobulin-deficient mice were as efficient as 
WT mice in controlling a lethal ZIKV i.c. infection (Figure 12). 
The inability of the few immunized β2-microblobulin-deficient 
mice to completely clear the infection could be attributed to the 
fact that these mice often display a substantially reduced level of 
Abs (36). Thus, again the results were consistent with a role of 
T cells when Ab levels are not optimal. Interestingly, some immu-
nized perforin/IFN-γ double-deficient mice also seemed to fail 
to completely clear the i.c. infection by day 7 post i.c. challenge, 
suggesting that effector cells (T cells and/or NK cells) might also 
FigUre 11 | In vivo depletion of T cells. Wild-type C57BL/6 mice were inoculated with 1 × 103 pfu Zika virus (ZIKV) i.v. and mice were challenged with 1 × 103 pfu 
ZIKV i.c. On day −1, 1, and 4 post i.c., mice were depleted of CD8 (αCD8) and/or CD4 (αCD4) T cells. Mice were weighed and monitored daily (a), and on day 7 
post i.c. challenge, brains were removed and viral titers were measured by a plaque assay (B). Groups of undepleted immunized and naïve mice were used as 
positive and negative controls, respectively. The detection limit for virus was determined as 250 pfu/g of brain. Each dot represents an individual animal and bars the 
medians of the groups. The weight curves depict the group medians. n = 3–5 mice/group, *p < 0.05. Immunized and naïve mice of the same strain is compared; 
the color of the star denotes the treated group used for statistical comparison. The results of one of two identical experiments are depicted.
FigUre 12 | CD8 T cells are not essential for protection against Zika virus (ZIKV). β2-microglobulin-deficient (β2m −/−) and CD8α-deficient (CD8−/−) (a) or IFN-γ/
perforin double-deficient (IFN-γ/Prf−/−) (B) mice were inoculated with 1 × 103 pfu ZIKV i.v. and 4 weeks later were challenged with 1 × 103 pfu ZIKV i.c. On day 7 post 
i.c. challenge, brains were removed and viral titers were measured by a plaque assay. For all deficient mice, a group of uninfected deficient mice was included for 
control. Additionally, wild-type (WT) C57BL/6 mice, inoculated with 1 × 103 pfu ZIKV i.v., and naive uninfected mice were used as positive and negative controls, 
respectively. The detection limit for virus in the brain was 250 pfu/g organ. Each dot represents an individual animal, and bars represent the medians of the groups. 
n = 4–5 mice/group, *p < 0.05.
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play a minor role in controlling the infection of B-cell replete 
mice (Figure 12).
Regarding the contribution of CD4 T cells, we administered 
1  ×  103  pfu ZIKV i.v. to MHC-II-deficient (Aβ−/−), CD40L-
deficient, and CXCR5-deficient mice, and 4 weeks later, we com-
pared the outcome of i.c. challenge to that in WT mice. Again, naive 
mice of each mouse strain were included for control (Figure 13). 
We observed that the absence of CD4 T  cells (in Aβ−/− mice) 
as well as their inability to provide T-cell help (CD40L−/−) can 
severely impair effective viral clearance following i.c. challenge, 
and both immunodeficient strains displayed levels of replicating 
virus in the CNS similar to the naive control groups. Immunized 
CXCR5-deficient mice experienced a milder infection following 
lethal i.c. challenge and did not display the same weight loss as 
FigUre 13 | CD4 T cells are essential for protection against Zika virus (ZIKV). MHC class II-deficient (Aβ−/−) (a,B) or CXCR5-deficient (CXCR5−/−) and CD40L-
deficient (CD40L−/−) (c,D) mice were inoculated with 1 × 103 pfu ZIKV i.v. and 4 weeks later were challenged with 1 × 103 pfu ZIKV i.c. Mice were weighed and 
monitored daily (a,c), and on day 7 post i.c. challenge, brains were removed and viral titers were measured by a plaque assay (B,D). For all deficient mice, a group 
of uninfected deficient mice was included for control. Additionally, wild-type (WT) C57BL/6 mice, inoculated with 1 × 103 pfu ZIKV i.v., and naive uninfected mice 
were used as positive and negative controls, respectively. The detection limit for virus in the brain was 250 pfu/g organ. Each dot represents an individual animal. 
The results illustrate the group medians. The weight curves depict the group medians. n = 4–5 mice/group, *p < 0.05. For the weight curves, immunized and naïve 
mice of the same strain have been compared, and the color of the star marks the immunized group used in the statistical comparison.
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the naive groups (data not shown); however, substantial viral 
replication was still found in the CNS of some of the former mice, 
which implies the need for efficient germinal center formation 
and isotype switching for optimal protection.
An overview of the knockout mouse strains used in this study 
and the level of protection induced by peripheral priming preced-
ing lethal i.c. challenge are shown in Table S1 in Supplementary 
Material.
DiscUssiOn
Even though ZIKV has been known for more than half a cen-
tury, a comprehensive analysis of the immune mechanisms that 
protect most immunocompetent hosts from developing severe 
disease has not been carried out before. In mice, little ZIKV 
replication can be detected in most organs unless early type I IFN 
activity is impaired, and mice treated with IFNAR-blocking Abs 
or equivalent genetically deficient mice are currently the favored 
model for studying aspects of ZIKV infection in mice (20–22). 
However, since type I IFN impacts not only the innate but also the 
adaptive immune response (37, 38), type I IFN-deficient models 
are not optimally suited to provide an in-depth analysis of the 
natural protective adaptive immune response. Therefore, based 
on our previous experiences with mice infected with the closely 
related YFV (24), we predicted that direct i.c. challenge might 
represent a means to bypass this early innate defense and induce 
clear virus associated disease that could be studied. Indeed, this 
prediction was fulfilled in both mouse strains tested (BALB/c and 
B6). Remarkably, peripheral inoculation with a low dose of the 
virus into type I IFN replete mice, which did not lead to detect-
able production of infectious virus in the spleen, nonetheless, did 
induce a protective host response. This made it possible for us to 
use fully type I IFN replete mice to study, which components of 
the adaptive immune system are essential to prevent reinfection 
with ZIKV.
As also recently reported by others (25, 39, 40), we found 
that peripheral ZIKV infection in WT mice induces both a 
humoral and a T-cell-mediated immune response. More impor-
tantly, fully competent, peripherally infected mice challenged 
i.c. 30 days later showed little if any evidence of disease, while 
matching naïve mice consistently became severely ill and had to 
be euthanized for humane reasons around day 8 post infection. 
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For subsequent interpretation of the results in gene-targeted 
mice, it should be pointed out that the induced disease did not 
appear to reflect immunopathology, since similar severe disease 
was observed in the naïve mice of all the tested mouse strains 
including TCRβ and CD8a knockouts. This is at variance to a 
recent report which claims an important role for CD8 T cells in 
causing hind-limb paralysis (41). Analysis of the virus level in 
the CNS of i.c. infected immune mice failed to reveal detectable 
virus replication in the brain of most of the immune mice at any 
time point after challenge, and even a 100- to 1,000-fold increase 
in the challenge dose did not lead to an early viral breakthrough, 
suggesting a very solid state of antiviral immunity in i.v. infected 
mice. A similar resistance to i.c. infection was observed in 
mice primed via the s.c. route, which supports the assumption 
that limited peripheral infection results in solid immunity. 
Protection against infection with the unrelated flavivirus, YFV 
was significant, but limited, consistent with the notion that 
there is some, but incomplete cross-reactivity between these two 
viruses. By gradually increasing the interval between peripheral 
immunization and subsequent i.c. challenge, we could dem-
onstrate that protective immunity was induced between 4 and 
7 days after virus inoculation, coinciding with the appearance 
of both neutralizing Abs and virus-specific CD8 T cells, and in 
both mouse strain tested clinical protection was very stable over 
time; thus, even 8  months after priming, mice challenged i.c. 
effectively controlled the infection and did not develop evidence 
of disease. Adoptive transfer of serum from immunized mice 
fully protected against clinical disease, while splenocytes from 
the same donors only marginally impacted virus levels in the 
CNS at day 7 after challenge of the recipients. This indicated 
that humoral immunity was most important in otherwise intact 
hosts, but cellular immunity might also play a role, perhaps as 
a backup when few specific Abs are present in the circulation at 
the time of infection.
For a more in-depth analysis of the adaptive immune response 
to Zika we used various gene-targeted mice, which were first 
primed through peripheral infection and challenged i.c. 30 days 
later. None of the immunodeficient mice developed obvious signs 
of disease during the priming phase indicating that none of the 
impaired gene functions individually were mandatory in order 
to survive a peripheral ZIKV challenge. However, neither TCR 
αβ T-cell-deficient nor B-cell-deficient mice were able to control 
subsequent infection of the CNS indicating that both cell types 
were required to resist i.c. infection. In B-cell-deficient mice, we 
could further show that CD8 T cells could serve as backup in the 
absence of circulating Abs, as indicated by a significantly higher 
level of virus in the CNS of CD8 T-cell depleted, B-cell-deficient 
mice. This is in contrast to the situation in WT mice where Abs are 
present prior to challenge. In this case, it was found that neither 
CD4 nor CD8 T cells are critically required in the effector phase, 
based on depletion of these cell subsets individually or combined 
immediately before i.c. challenge.
It should perhaps be noted that generally viral loads in the 
CNS of naïve mice day 7 post i.c. challenge tended to be slightly 
higher in the most severely immunocompromised, gene-targeted 
mice compared to naïve WT mice. This could reflect that com-
ponents of the adaptive immune system start to play a role even 
in unimmunized WT mice around this time point. Consistent 
with this possibility, we observed significant T-cell and mono-
cyte/macrophage infiltration in previously unimmunized WT 
mice at the time when we have to euthanize them based on the 
severity of their clinical symptoms (Nazerai et al., manuscript in 
preparation).
Eliminating the T cells prior to the challenge does not address 
their role during priming or even as tissue resident memory cells 
since these might not be efficiently depleted by the Ab injection. 
Therefore, to further map the role of T cells, we immunized mice 
with more specific deficiencies within their T-cell compartment. 
Overall, CD8 KO mice and most beta2-microglobulin-deficient 
mice controlled the challenge infection quite well; the few 
exceptions among the beta2-microglobulin-deficient mice could 
reflect the well-known fact that these mice not only lack CD8 
T  cells but also catabolize their Abs faster than normal mice 
and for that reason carry lower levels of Abs in addition to their 
T-cell defect (42). Therefore, CD8 T cells might play a role when 
Abs levels are suboptimal. The finding that a few perforin/IFN-γ 
double-deficient mice display a similar phenotype could also 
point to a back-up function of virus-specific effector T cells, as it 
is also indicated by our findings in CD8-depleted B-cell-deficient 
mice.
Consistent with a key role for B cells and antibodies, mice 
that lack CD4 T cells or the capacity to interact with B cells were 
found to be markedly impaired in their capacity to resist the 
i.c. challenge. Obviously, we cannot be certain that the require-
ment for CD4 T-cell help only pertains to the B cell response, 
but given the minor role of effector CD8 T cells, and the fact 
that effector CD4 T cells were not found to be required during 
the challenge, lack of help to the B cells is by far the most likely 
interpretation of the results. Also the observation that some 
CXCR5-deficient mice are impaired in their ability to control 
the challenge, despite the fact that germinal center formation 
and isotype switching may also occur to some extent in these 
mice (43), strongly support the idea that help to B  cells and 
efficient germinal center formation is important for the develop-
ment of optimal resistance to reinfection. Interestingly, this is in 
contrast to the situation in YFV immunized mice where CXCR5 
deficiency did not impact resistance to i.c. challenge with the 
homologous virus (24).
In conclusion, using a peripheral prime, i.c. challenge 
approach, we have been able to establish a murine ZIKV chal-
lenge model in type I IFN replete mice. Others have also studied 
ZIKV infection in WT mice, but either the mechanism of protec-
tion, particularly the role of abs, was not explored (25, 39, 40) 
or newborn animals known to be deficient in their capacity for 
a type I IFN response were used (44, 45). Another important 
difference is that we have used low doses (103 pfu) of virus i.v. or 
s.c. for immunization of the animals, not intraperitoneal infec-
tion with relatively high doses (≥104 pfu). The current model is 
well suited for analysis of the natural adaptive immune response 
to ZIKV as well as for early, preclinical evaluation of potential 
vaccine candidates. In this study, we focused on the adaptive 
immune mechanisms underlying resistance to reinfection with 
ZIKV. Our results point to a critical role for humoral immunity, 
even though the details of how the Abs work in  vivo is still 
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unknown. This conclusion is in agreement with some of the first 
reports on vaccination against ZIKV (46, 47), but not with more 
recent reports, which have emphasized the role of CD8 T cells 
(21, 39, 40). According to our findings, CD8 T cells do make a 
minor contribution, but it is also very clearly documented that 
they are not pivotal in mice with sufficient preformed specific 
Abs. Consequently, an efficient prophylactic vaccine against 
ZIKV infection needs to induce at least a potent Ab response. 
Probably, a vaccine would work even more efficiently if it also 
induced a CD8 T  cell response that could provide additional 
immunity in  situations where Abs levels are insufficient for 
complete protection. Both our current results and recent results 
from other groups using type I IFN-deficient models (21, 39, 40) 
support this conclusion. It is also of considerable interest to note 
that asymptomatic, peripheral infection with ZIKV suffices to 
induce long-lasting protective immunity. Even though infec-
tion of the fetus has not been addressed in this study, the solid 
immunity observed following low dose peripheral infection 
strongly suggests that only the primary infection carries a real 
risk for fetal malformation. The implications of this prediction 
is that once a human population has thoroughly been exposed 
to ZIKV, most would eventually become resistant to subsequent 
infections, and the frequency of malformations would decline 
markedly. Even those uninfected might be protected through 
herd immunity unless the virus is able to establish and maintain 
itself in a suitable non-human host. Only in the latter case will a 
vaccine be required in the long run.
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